TriNetX and Regeneron agreed to link genomic and proteomic data for drug discovery and development, with TriNetX providing exclusive access to de-identified health data from roughly 300 million individuals. The deal is positioned as a large-scale data bridge that can connect molecular profiles with real-world clinical outcomes. For Regeneron, the value is expected to come from enabling hypothesis testing at the interface of discovery biology and downstream development signals, while TriNetX expands its role as an intermediary for interoperable datasets. The agreement will be watched closely for governance details—how data are licensed, what discovery use cases are permitted, and how privacy controls are applied—especially given the scale of the underlying cohort.